PCML
MIST icon

Pavaki Capital Management LLC’s Milestone Pharmaceuticals MIST Stock Holding History

Pavaki Capital Management LLC’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
9,067,848
+5,000
+0.1% +$7.99K 4.24% 5
2026
Q1 		$10.8M Buy
9,062,848
+563,933
+7% +$987K 4.58% 4
2025
Q4 		$17.2M Buy
+8,498,915
New +$18.3M 6.73% 2

Other funds holding MIST

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
BRG
Bay Rivers Group Williamsburg, Virginia $293M AUM 48.17% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
OE
October Effect Virginia Beach, Virginia $106M AUM 85.28% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Pavaki Capital Management LLC's MIST Position: Q2 2026 in Review

Pavaki Capital Management LLC increased its Milestone Pharmaceuticals (MIST) stake by 0.06% in Q2 2026, buying an estimated $7.99K and bringing the position to 9,067,848 shares worth $12.2M. The position accounts for 4.24% of the portfolio, ranked #5.

Pavaki Capital Management LLC first reported a position in MIST in Q4 2025 and has held it in 3 quarters since. The position peaked at $17.2M in Q4 2025. 25 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Pavaki Capital Management LLC held 9,067,848 shares of Milestone Pharmaceuticals worth $12.2M as of Q2 2026.
  • Pavaki Capital Management LLC bought 5,000 Milestone Pharmaceuticals shares in Q2 2026, an estimated $7.99K.
  • Milestone Pharmaceuticals made up 4.24% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #5 holding.
  • Pavaki Capital Management LLC first reported a position in Milestone Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management LLC's Milestone Pharmaceuticals position peaked at $17.2M in Q4 2025.
  • 25 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.